USSN: 10/650,369

PATENT

AMENDMENT

Amendments to the Claims:

The following listing reflects amendments to the claims and replaces all prior versions and listings of claims in this application.

1-10. (Cancelled)

- 11. (Currently amended) The polynucleotide sequence of claim 10 15, wherein the multiple epitopes fusion polypeptide further comprises a signal sequence.
- 12. (Currently amended) The polynucleotide sequence of claim 10 15, wherein the multiple epitopes fusion polypeptide further comprises a transmembrane sequence.
- 13. (Currently amended) The polynucleotide sequence of claim 10 15, wherein the multiple epitope epitopes fusion polypeptide comprises GapC epitopes from Streptococcus dysgalactiae, Streptococcus agalactiae and Streptococcus parauberis.
- 14. (Previously presented) The polynucleotide sequence of claim 13, wherein said more than one GapC epitopes are separated by a spacer amino acid sequence.
- 15. (Currently amended) The A polynucleotide sequence of claim 10 encoding an immunogenic multiple epitopes fusion polypeptide comprising more than one *Streptococcus* GapC epitope from more than one *Streptococcus* species, or the complement thereof, wherein said immunogenic polypeptide comprises an epitope from a Streptococcus GapC protein corresponding to
- (a) the amino acid sequences shown at amino acid positions 62 to 81, inclusive, of SEQ ID NOS: 12, 14, 16, 18 and 20;

USSN: 10/650,369

PATENT

(b) the amino acid sequences shown at about amino acid positions 102 to 112, inclusive, of SEQ ID NOS: 12, 14, 16, 18 and 20;

- (c) the amino acid sequences shown at about amino acid positions 165 to 172, inclusive, of SEQ ID NOS: 12, 14, 16, 18 and 20;
- (d) the amino acid sequences shown at about amino acid positions 248 to 271, inclusive, of SEQ ID NOS: 12, 14, 16, 18 and 20; and
- (e) the amino acid sequences shown at about amino acid positions 286 to 305, inclusive, of SEQ ID NOS: 12, 14, 16, 18 and 20.
- 16. (Currently amended) The polynucleotide sequence of claim 15, wherein the multiple epitopes fusion polypeptide comprises an amino acid sequence having at least 80% sequence identity to the contiguous sequence of amino acids depicted at positions 27-448 of the amino acid sequence depicted in SEQ ID NO:22.
- 17. (Previously presented) The polynucleotide sequence of claim 16, further comprising a signal sequence.
- 18. (Previously presented) The polynucleotide sequence of claim 17, wherein the signal sequence comprises the amino acid sequence depicted at positions 1-26 of SEQ ID NO:22.
 - 19. (Cancelled)
 - 20. (Original) A recombinant vector comprising:
 - (a) the isolated polynucleotide of claim 11; and
- (b) at least one control element operably linked to said isolated polynucleotide, whereby said coding sequence can be transcribed and translated in a host cell.
 - 21. (Original) A recombinant vector comprising:
 - (a) the isolated polynucleotide of claim 12; and

USSN: 10/650,369

PATENT

(b) at least one control element operably linked to said isolated polynucleotide, whereby said coding sequence can be transcribed and translated in a host cell.

- 22. (Original) A recombinant vector comprising:
- (a) the isolated polynucleotide of claim 13; and
- (b) at least one control element operably linked to said isolated polynucleotide, whereby said coding sequence can be transcribed and translated in a host cell.
 - 23. (Original) A recombinant vector comprising:
 - (a) the isolated polynucleotide of claim 14; and
- (b) at least one control element operably linked to said isolated polynucleotide, whereby said coding sequence can be transcribed and translated in a host cell.
 - 24. (Original) A recombinant vector comprising:
 - (a) the isolated polynucleotide of claim 15; and
- (b) at least one control element operably linked to said isolated polynucleotide, whereby said coding sequence can be transcribed and translated in a host cell.
 - 25. (Original) A recombinant vector comprising:
 - (a) the isolated polynucleotide of claim 16; and
- (b) at least one control element operably linked to said isolated polynucleotide, whereby said coding sequence can be transcribed and translated in a host cell.
 - 26. (Original) A recombinant vector comprising:
 - (a) the isolated polynucleotide of claim 17; and
- (b) at least one control element operably linked to said isolated polynucleotide, whereby said coding sequence can be transcribed and translated in a host cell.
 - 27. (Original) A recombinant vector comprising:

USSN: 10/650,369

PATENT

the isolated polynucleotide of claim 18; and

- (b) at least one control element operably linked to said isolated polynucleotide, whereby said coding sequence can be transcribed and translated in a host cell.
- 28. (Cancelled)
- 29. (Original) A host cell comprising the recombinant vector of claim 20.
- 30. (Original) A host cell comprising the recombinant vector of claim 21.
- 31. (Original) A host cell comprising the recombinant vector of claim 22.
- 32. (Original) A host cell comprising the recombinant vector of claim 23.
- 33. (Original) A host cell comprising the recombinant vector of claim 24.
- 34. (Original) A host cell comprising the recombinant vector of claim 25.
- 35. (Original) A host cell comprising the recombinant vector of claim 26.
- 36. (Original) A host cell comprising the recombinant vector of claim 27.
- 37. (Cancelled)
- 38. (Currently amended) A method for producing a multiple epitope epitopes fusion polypeptide, said method comprising culturing the cells of claim 29 under conditions for producing said polypeptide.

USSN: 10/650,369

PATENT

39. (Currently amended) A method for producing a multiple epitope epitopes fusion polypeptide, said method comprising culturing the cells of claim 30 under conditions for producing

said polypeptide.

40. (Currently amended) A method for producing a multiple epitope epitopes fusion

polypeptide, said method comprising culturing the cells of claim 31 under conditions for producing

said polypeptide.

41. (Currently amended) A method for producing a multiple epitope epitopes fusion

polypeptide, said method comprising culturing the cells of claim 32 under conditions for producing

said polypeptide.

42. (Currently amended) A method for producing a multiple epitope epitopes fusion

polypeptide, said method comprising culturing the cells of claim 33 under conditions for producing

said polypeptide.

43. (Currently amended) A method for producing a multiple epitope epitopes fusion

polypeptide, said method comprising culturing the cells of claim 34 under conditions for producing

said polypeptide.

44. (Currently amended) A method for producing a multiple epitope epitopes fusion

polypeptide, said method comprising culturing the cells of claim 35 under conditions for producing

said polypeptide.

45. (Currently amended) A method for producing a multiple epitope epitopes fusion

polypeptide, said method comprising culturing the cells of claim 36 under conditions for producing

said polypeptide.

46-75. (Cancelled)

6